New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.
Lonza, WuXi Biologics, and Baxter Healthcare announce facility expansions and updates. Repligen reports revenue growth, while ...
Novo Nordisk said Thursday that it plans to eventually halt all of its human insulin pen production globally, ...
The global pharma company whose name rhymes with the capital of China wants people to know that it is not in fact a Chinese ...
Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for ...
Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...
Ascidian Therapeutics CEO Michael Ehlers is leaving the venture investor that serves as his home base and will join MPM ...
Summit Therapeutics and its Chinese partner Akeso have a few competitors now.
Zai Lab announces $200M share offering amid 47% revenue growth and plans for KarXT submission in China. Multiple companies report changes: Kronos Bio seeks alternatives, Allogene halts trial ...
The FDA has cleared PTC Therapeutics’ gene therapy for AADC deficiency, an ultra-rare disease that impacts the ...
The amylin field is heating up ahead of Novo Nordisk's much-anticipated CagriSema readout later this year. On Wednesday, ...
The GAO report highlights FDA's drug inspection program challenges, including 36% fewer inspections in 2023 compared to 2019 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback